Login to Your Account



(Site)-Specifically, Oncology

Re-verb: Conjugates Lure BMS to Ambrx Deal Number Three

By Randy Osborne
Staff Writer

Monday, May 6, 2013

An existing partner with two other deals jumped aboard Ambrx Inc.'s site-specific, antibody drug conjugate (ADC) bandwagon, as Bristol-Myers Squibb Co. provided $15 million up front plus funding for discovery and research, as well as milestone payments of that could total $97 million per oncology product emerging from the collaboration.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription